Sickle cell: Gov’t agrees to provide Hydroxyurea under NHIS
The government has agreed that hydroxyurea, a modifying therapy for sickle cell patients, will now be provided under the National Health Insurance Scheme (NHIS).
Vice-President Mahamudu Bawumia disclosed in a Facebook post as Ghana joined the rest of the world to mark Sickle Cell Awareness Day on 19 June 2021.
The decision to provide hydroxyurea under the NHIS was taken in consultation with stakeholders like the Sickle Cell Foundation, the NHIA and Novartis, a global healthcare company based in Switzerland.
Sickle cell anaemia is an inherited red blood cell disorder in which there are not enough healthy red blood cells to carry oxygen throughout the body.
The symptoms of sickle cell anaemia usually show up at a young age.
They may appear in babies as early as four months old but generally occur around the six-month mark.
While there are multiple types of SCD, they all have similar symptoms, which vary in severity.
These include excessive fatigue or irritability, anaemia, fussiness, bedwetting, associated kidney problems and jaundice.
The others are swelling and pain in hands and feet, frequent infections, pains in the chest, back, arms, or legs.
Children are only at risk for sickle cell disease if both parents carry sickle cell traits.
Trending News
Today's 'dumsor' due to rainstorm – ECG
10:14Debt restructuring: No MoU reached with bilateral creditors – IMF
08:19Ghana-Vietnam deepen relations
07:58NDC to officially introduce Prof Naana Opoku-Agyemang as running mate tomorrow
10:15Crusaders Against Corruption-Ghana denies joining Alan’s Alliance for Revolutionary Change
07:52Akufo-Addo and Ouattara inaugurate Côte d'Ivoire-Ghana Cocoa Initiative Secretariat today
07:45Lift veil on assets declared by public officials – Osafo-Maafo
14:33TEWU elects 1st female national chairperson
10:32Akufo-Addo commissions Kumasi Thermal Power Plant and Genser Energy Kumasi Pipeline
06:27GRASAG optimistic about Mahama's 24-Hour economy
10:16